LabCorp (LH) Could See a Hit from Aetna/Coventry Health Deal

Article Stock Quotes (6) Comments (0)

In addition to implications for CVS Caremark (NYSE: CVS) and Express Scripts (Nasdaq: ESRX), today's Aetna (NYSE: AET) buyout of Coventry Health (NYSE: CVH) could also hurt LabCorp (NYSE: LH) in favor of Quest Diagnostics (NYSE: DGX).

Piper Jaffray analyst Kevin Ellich said Coventry's testing volume will now likely shift to Quest Diagnostics from LabCorp after the deal.

Despite the possible loss of business the impact will be manageable. The firm sees LabCorp revenue decreasing about $20 million, with an EPS impact of about $0.03.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
• UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
• Two Key Things are Going Against Apple (AAPL) in This Potential $10B Market

Create E-mail Alert Related Categories

Analyst Comments, Trader Talk

Related Entities

Piper Jaffray

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?